ASX ANNOUNCEMENT ASX: CVB st 21 October 2026 Appendix 4C & quarterly activity report – period ended 30 September 2026 Summary of key activities • Purchase orders (POs) secured during Q1 FY27 totalled five (5) devices, all HiRise™ systems, marking the strongest Q1 sales result to date. •...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 10 pages · English
Summary by 6ix AI
The report highlights the receipt of purchase orders for five HiRise™ devices and FDA clearance for its Bone Mineral Density technology. Additionally, Curvebeam Ai is advancing its strategy in China, having received regulatory clearance that is expected to trigger significant milestone payments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
In the deck
Story so far
Earlier from CurveBeam AI
- Q1 FY27 Quarterly Results Investor Webinar
- Change in substantial holding - Intellivision Holdings
- Change in substantial holding - Arun & Susmita Singh
- CVB Achieves NMPA Approval for HiRise in China
- Trading Halt
Later from CurveBeam AI
- CVB Quarterly Investor Presentation - Q1 FY27
- Director Appointment - Dan Pryor NED & ARC Chair
- Notification regarding unquoted securities - CVB
- Initial Director's Interest Notice - Dan Pryor
- Notice of Annual General Meeting/Proxy Form
Follow CurveBeam AI into a list and get an email when it puts out news.
Follow CurveBeam AI